IN THIS SERIES

In 2022, the United States Supreme Court overturned Roe v. Wade, ending the federal constitutional right to abortion. But the legal fight did not end there.

This series explains two major cases currently before the Supreme Court that could further reshape abortion access across the country. The first case challenges the FDA’s approval and regulation of mifepristone, the most commonly used abortion pill. The second questions whether hospitals in states with abortion bans must still provide emergency abortion care under federal law.

Both cases have national implications. Their outcomes could affect access to care, mail-order medication, emergency treatment, and the limits of state and federal authority.

This series breaks down what the Court is deciding, why it matters, and how to stay informed and engaged. All information is sourced from verified, nonpartisan, and fact-based organizations.

These decisions are expected in June 2025. Until then, the future of reproductive rights remains uncertain and active.

Case Studies